drugset / Trial / NCT07603401
Expanded Access Program of Bitopertin For Participants With EPP or XLP
Summary
The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bitopertin | Small molecule | 60 mg | Oral |